Page last updated: 2024-09-03

olmesartan medoxomil and Coronary Disease

olmesartan medoxomil has been researched along with Coronary Disease in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hayashida, Y; Morishita, T; Nakashima, Y; Nakata, S; Sasaguri, Y; Suda, O; Tasaki, H; Toyohira, Y; Tsujimoto, T; Tsutsui, M; Ueno, S; Ueta, Y; Yanagihara, N	1
Dong, J; Fujii, S; Furumoto, T; Goto, D; Imagawa, S; Kitabatake, A; Mishima, T; Nakai, Y; Sobel, BE; Zaman, AK	1

Other Studies

2 other study(ies) available for olmesartan medoxomil and Coronary Disease

Article	Year
Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arteriosclerosis, thrombosis, and vascular biology, 2004, Volume: 24, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Coronary Disease; Enzyme Induction; Homocysteine; Imidazoles; Infusion Pumps, Implantable; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microcirculation; Myocardium; NG-Nitroarginine Methyl Ester; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Nitrites; Olmesartan Medoxomil; omega-N-Methylarginine; Oxidative Stress; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Superoxides; Tetrazoles; Thiazepines	2004
Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. Journal of molecular and cellular cardiology, 2004, Volume: 37, Issue:2 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Collagen Type I; Coronary Disease; Coronary Vessels; Fibrosis; Heart Ventricles; Imidazoles; Insulin; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Male; Matrix Metalloproteinase 9; Mice; Mice, Obese; Obesity; Olmesartan Medoxomil; Phosphorylation; Plasminogen Activator Inhibitor 1; Tetrazoles; Thiazepines; Transforming Growth Factor beta	2004

Article

Year

Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress.

Arteriosclerosis, thrombosis, and vascular biology, 2004, Volume: 24, Issue:9

Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Coronary Disease; Enzyme Induction; Homocysteine; Imidazoles; Infusion Pumps, Implantable; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microcirculation; Myocardium; NG-Nitroarginine Methyl Ester; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Nitrites; Olmesartan Medoxomil; omega-N-Methylarginine; Oxidative Stress; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Superoxides; Tetrazoles; Thiazepines

2004

Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity.

Journal of molecular and cellular cardiology, 2004, Volume: 37, Issue:2

Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Collagen Type I; Coronary Disease; Coronary Vessels; Fibrosis; Heart Ventricles; Imidazoles; Insulin; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Male; Matrix Metalloproteinase 9; Mice; Mice, Obese; Obesity; Olmesartan Medoxomil; Phosphorylation; Plasminogen Activator Inhibitor 1; Tetrazoles; Thiazepines; Transforming Growth Factor beta

2004